12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zelboraf vemurafenib regulatory update

The U.K.'s NICE issued final guidance recommending the use of Zelboraf vemurafenib from Roche to treat unresectable or metastatic melanoma in patients with BRAF V600 mutations - its approved indication. The recommendation is contingent on Roche providing Zelboraf...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >